Publicação
Development of antibody-directed therapies: quo vadis?
| dc.contributor.author | Rodrigues, Tiago | |
| dc.contributor.author | Bernardes, Gonçalo J. L. | |
| dc.date.accessioned | 2021-12-02T15:42:53Z | |
| dc.date.available | 2021-12-02T15:42:53Z | |
| dc.date.issued | 2018 | |
| dc.description | © 2018 The Authors. Published by Wiley-VCH Verlag GmbH & Co. KGaA. This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. | pt_PT |
| dc.description.abstract | Less is more: The efficacy of antibody-drug conjugates (ADCs) for cancer therapy is traditionally associated with cleavable linkers for payload release. Evidence now suggests that simpler constructs without cleavable moieties can afford more stable and effective ADCs. | pt_PT |
| dc.description.sponsorship | We thank FCT Portugal (iFCT) the EU (Marie Sklodowska-Curie ITN ProteinConjugates) and the EPSRC to G.J.L.B. T.R. is a Marie Sklodowska-Curie Fellow (Grant 743640). G.J.L.B. is a Royal Society URF and recipient of an ERC StG (TagIt). | pt_PT |
| dc.description.version | info:eu-repo/semantics/publishedVersion | pt_PT |
| dc.identifier.citation | Angew Chem Int Ed Engl. 2018 Feb 19;57(8):2032-2034 | pt_PT |
| dc.identifier.doi | 10.1002/anie.201712185 | pt_PT |
| dc.identifier.eissn | 1521-3773 | |
| dc.identifier.issn | 1433-7851 | |
| dc.identifier.uri | http://hdl.handle.net/10451/50253 | |
| dc.language.iso | eng | pt_PT |
| dc.peerreviewed | yes | pt_PT |
| dc.publisher | John Wiley & Sons, Inc. | pt_PT |
| dc.relation | TRPV1-targeted ligand-drug conjugates to treat prostate cancer | |
| dc.relation.publisherversion | https://onlinelibrary.wiley.com/journal/15213773?tabActivePane=undefined | pt_PT |
| dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ | pt_PT |
| dc.subject | Anti-tumor agents | pt_PT |
| dc.subject | Antibody-drug conjugates | pt_PT |
| dc.subject | Bioconjugation | pt_PT |
| dc.subject | Drug delivery | pt_PT |
| dc.subject | Linkers | pt_PT |
| dc.title | Development of antibody-directed therapies: quo vadis? | pt_PT |
| dc.type | journal article | |
| dspace.entity.type | Publication | |
| oaire.awardTitle | TRPV1-targeted ligand-drug conjugates to treat prostate cancer | |
| oaire.awardURI | info:eu-repo/grantAgreement/EC/H2020/743640/EU | |
| oaire.citation.endPage | 2034 | pt_PT |
| oaire.citation.issue | 8 | pt_PT |
| oaire.citation.startPage | 2032 | pt_PT |
| oaire.citation.title | Angewandte Chemie International Edition | pt_PT |
| oaire.citation.volume | 57 | pt_PT |
| oaire.fundingStream | H2020 | |
| person.familyName | Bernardes | |
| person.givenName | Gonçalo | |
| person.identifier.orcid | 0000-0001-6594-8917 | |
| person.identifier.scopus-author-id | 14046757500 | |
| project.funder.identifier | http://doi.org/10.13039/501100008530 | |
| project.funder.name | European Commission | |
| rcaap.rights | openAccess | pt_PT |
| rcaap.type | article | pt_PT |
| relation.isAuthorOfPublication | d1a48067-77b1-4413-b1c7-602fb18c62c0 | |
| relation.isAuthorOfPublication.latestForDiscovery | d1a48067-77b1-4413-b1c7-602fb18c62c0 | |
| relation.isProjectOfPublication | f5c16c5d-a441-4252-8c7b-db3515443498 | |
| relation.isProjectOfPublication.latestForDiscovery | f5c16c5d-a441-4252-8c7b-db3515443498 |
Ficheiros
Principais
1 - 1 de 1
A carregar...
- Nome:
- Development_antibody.pdf
- Tamanho:
- 631.65 KB
- Formato:
- Adobe Portable Document Format